DARMSTADT, Germany, August 31, 2017 /PRNewswire/ --
Not intended for U.K. or U.S. based media
ESMO 2017 abstract #
Erbitux(R): 576P, 593P, 1068P, 1579P; avelumab: 1227P, 913P, 1377TiP, 882P, 856P;
M6620 (ATR inhibitor): 242PD; M2698 (dual p70S6K/Akt inhibitor): 370PD, 393P; tepotinib
(c-Met kinase inhibitor): 701P
- Data to showcase Merck's strong and diverse pipeline ranging from
to DNA damage response
- Avelumab data validate potential in hard-to-treat cancers and highlight progress of
the JAVELIN clinical development program
- First stand-alone data in mTNBC for ATR inhibitor (M6620) from Merck's
portfolio in DNA damage response
Merck, a leading science and technology company, today announced it will present
for a number of tumor types across its rapidly evolving pipeline. A total of 23
representing five therapeutic agents, will highlight the company's expanding scientific
expertise at this year's European Society for Medical Oncology congress (ESMO 2017;
September 8-12, Madrid, Spain).
Data to be presented include continued reinforcement of the role of established
Erbitux(R) (cetuximab) as a standard of care therapy, with quality of life (QoL) data
colorectal cancer (CRC) and real-world data in both CRC and squamous cell carcinoma of
head and neck (SCCHN); updated efficacy and safety data for avelumab in metastatic
cell carcinoma (mMCC) and urothelial carcinoma (UC) among other cancers; and new data
updates from Merck's rapidly evolving pipeline, including first stand-alone data in
metastatic triple negative breast cancer (mTNBC) from potential first-in-class ataxia
telangiectasia and Rad3-related protein (ATR) inhibitor M6620* (also known as VX-970).
"The Merck Oncology Franchise has had a momentous year, particularly with the
regulatory milestones achieved for avelumab. The story continues to evolve at ESMO 2017
from our legacy with Erbitux to our diverse and robust pipeline which has potential
molecules that could become new standards of care," said Luciano Rossetti, Executive
President, Global Head of Research & Development at the biopharma business of Merck.
data reinforce Merck's commitment to pursuing approaches that will bring important
benefits to patients and transform the way cancer is treated."
Merck's innovative approach and strategic collaborations in oncology are
through the ongoing partnership with Pfizer, and the significant progress of avelumab.
Granted two accelerated approvals** by the U.S. Food and Drug Administration (FDA) this
year, more recently the Committee for Medicinal Products for Human Use (CHMP) of the
European Medicines Agency (EMA) has adopted a positive opinion recommending the
of avelumab as monotherapy for the treatment of adult patients with mMCC. ESMO 2017
includes new data for avelumab in the treatment of mMCC, a rare and aggressive skin
and 12-month follow-up data in pre-treated patients with locally advanced or
UC. The progress of the broader JAVELIN clinical development program will also be
highlighted, with updated data in hard-to-treat tumors such as metastatic
The addition of the recently acquired Vertex DNA damage response (DDR) portfolio to
its own in-house DDR platform has positioned Merck as one of the key players in the DDR
field. The company's broad DDR portfolio includes inhibitors for enzymes of major DDR
pathways, such as ATR, DNA-PK and ATM. At ESMO 2017, first data will be presented for
inhibitor M6620 in metastatic triple-negative breast cancer (mTNBC). M6620 is currently
being investigated in several ongoing Phase I trials across a variety of tumor types.
Other pipeline updates will include data on the potential first-in-class dual
p70S6K/Atk inhibitor M2698*; and tepotinib***, a highly selective c-Met kinase
in patients with advanced hepatocellular carcinoma (HCC).
Product related information contained herein is subject to local product approval
can therefore vary from country to country. For information relevant to your country,
please check in with local regulatory authorities.
*M6620, M2698 and tepotinib are under clinical investigation and have not been
to be safe and effective. There is no guarantee any product will be approved in the
sought-after indication by any health authority worldwide.
***Tepotinib is the proposed International Non-proprietary Name (INN) for the c-Met
kinase inhibitor (also known as MSC2156119J).
Notes to editors
Accepted Merck-supported key abstracts at ESMO 2017 are listed below. In addition,
number of abstracts with data from investigator-sponsored studies have been accepted,
including abstracts related to Erbitux (not listed).
Date / Time
Title Lead Author Abstract # (CEST) Location
JAVELIN Lung 100:
updated design of
a phase 3 trial of
lung cancer September 9
(NSCLC) Reck M. 1377TiP 13:15 - 14:15 Hall 8
cell carcinoma September 10
(mMCC). D'Angelo S.P. 1227P 13:15-14:15 Hall 8
results from the
JAVELIN Solid Le Tourneau September 10
Tumor trial C. 913P 13:15-14:15 Hall 8
(A+Ax) on tumor
size (TS) compared
data of sunitinib
(S) as evaluated
by a modeling and
simulation (MS) September 10
approach Zheng J. 882P 13:15-14:15 Hall 8
carcinoma (mUC) in
the phase 1b
with greater than
or equal to6
follow-up in all September 10
patients Apolo A.B. 856P 13:15-14:15 Hall 8